Product Details             

• Isotype Control

• Brilliant Violet 421™ Rat IgG2b, κ Isotype Ctrl

• Verified Reactivity

• Mouse

• Antibody Type

• Monoclonal

• Host Species

• Rat

• Immunogen

• Mouse CTL clone V4

• Formulation

• Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

• Preparation

• The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.

• Concentration

• µg sizes: 0.2 mg/mL
  µL sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)

• Storage & Handling

• The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

• Application

•                            

  FC - Quality tested
  ICC - Verified

  SB - Reported in the literature, not verified in house

• Recommended Usage

• Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.125 µg per million cells in 100 µl volume. For flow cytometric staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
  
  Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

  
  Learn more about Brilliant Violet™.
  
  This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

• Excitation Laser

• Violet Laser (405 nm)
  

• Application Notes

• Additional reported applications (for the relevant formats) include: blocking of CD4⁺ T cell activation^1,4,11, thymocyte costimulation³, in vitro and in vivo depletion^2,5-8, blocking of egg-sperm cell adhesion^1,4, immunohistochemical staining of acetone-fixed frozen sections^9,10, immunoprecipitation^1,2, and spatial biology (IBEX)^12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

• Additional Product Notes

• Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

• Application References
  
  (PubMed link indicates BioLegend citation)

• See More

2. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)

4. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)

6. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)

8. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)

10. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)

12. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)

14. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)

16. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)

18. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)

20. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)

22. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)

24. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed

• Product Citations

• See More

1. Cignarella F et al. 2018. Cell metabolism. 27(6):1222-1235 . PubMed

2. Xu J et al. 2018. Cell. 173(3):762-775 . PubMed

3. Garg G et al. 2019. Cell reports. 26(7):1854-1868 . PubMed

4. Goswami M, et al. 2019. Biomed Opt Express. 10:151. PubMed

5. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed

6. Bennion BG, et al. 2019. J Virol. 93. PubMed

7. Silva DA, et al. 2019. Nature. 565:186. PubMed

8. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed

9. Runge EM, et al. 2020. J Neuroinflammation. 17:121. PubMed

10. Annu K, et al. 2020. Sci Rep. 10:2359. PubMed

11. Han Y, et al. 2020. Nat Commun. 11:1776. PubMed

12. Huai W, et al. 2019. J Exp Med. 216:772. PubMed

• RRID

• AB_10900241                                (BioLegend Cat. No. 100437)                                
  AB_2562557                                (BioLegend Cat. No. 100443)                                
  AB_11203718                                (BioLegend Cat. No. 100438)